Nevertheless, some pre-clinical evidence encourages the association of BTZ with other antitumor agents in colon cancer models to get synergistic effects (Caldiran et al., 2023; Celesia et al., 2022b; Park et al., 2018; Qing et al., 2021). Here, CASC3 is linked to colonic neoplasm.